Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases

Nephrology Dialysis Transplantation

Volumn 28, Issue 2, 2013, Pages 405-412

  Morales, Enrique ^a   Millet, Victor Gutiérrez ^a   Rojas Rivera, Jorge ^b   Huerta, Ana ^a   Gutiérrez, Eduardo ^a   Gutiérrez Solís, Elena ^a   Egido, Jesús ^b   Praga, Manuel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

aldosterone; mineralocorticoid receptor blocker; proteinuria; renoprotective; spironolactone

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CATION EXCHANGE RESIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; POTASSIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RENAL PROTECTION;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; COHORT STUDIES; COMORBIDITY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POTASSIUM; PROSPECTIVE STUDIES; PROTEINURIA; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84874521311     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs429     Document Type: Article

References (26)

1. Aldigier JC, Kanjanbuch T, Ma LJ et al. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005; 16: 3306-3314 (Pubitemid 46187550)
2. Fujisawa G, Okada K, Muto S et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004; 66: 1493-1502 (Pubitemid 39298382)
3. Gekle M, Grossmann C. Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch 2009; 458: 231-246
4. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors of angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 2: 199-211
5. Bertochio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade an emerging paradigm in chronic kidney disease. Kidney Int 2011; 79: 1051-1060
6. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-2123 (Pubitemid 44871374)
7. Van den Meiracker AH, Baggen RG, Pauli S et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24: 2285-2292 (Pubitemid 44611039)
8. Furumatsu Y, Nagasawa Y, Tomida K et al. Effect of renin-angiotensin- aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spirnolactone, to combination treatment with angiotensin-converting enzyme inhibitor and angiotensine II receptor blocker. Hypertens Res 2008; 31: 59-67 (Pubitemid 351325616)
9. Chrysostomou A, Pedagogos E, MacGregor A et al. Double-blind, placebo controlled study on the effect of aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262
10. Epstein M, Williams GH, Weinberger M et al. Selective aldosterone blockade with eplerenone reduces proteinuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951
11. Rachmani R, Slavachevsky I, Amit M et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21: 471-475 (Pubitemid 38608536)
12. Rossing K, Schjoedt KJ, Smidt UM et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-2112 (Pubitemid 41242452)
13. Schjoedt KJ, Rossing K, Juhl TR et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836 (Pubitemid 43251030)
14. Schjoedt KJ, Rossing K, Juhl TR et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542 (Pubitemid 44141580)
15. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts longterm stability of renal function. Kidney Int 1997; 51: 793-797 (Pubitemid 27157964)
16. Holtkamp FA, De Zeeuw D, Thomas MC et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011; 80: 282-287
17. Rossignol P, Cleland JG, Bhandari S et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation 2012; 125: 271-279
18. Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010; 6: 261-273
19. Nagase M, Yoshida S, Shibata S et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006; 17: 3438-3446 (Pubitemid 44865286)
20. De Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004; 43: 41-47 (Pubitemid 38031909)
21. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321 (Pubitemid 36384098)
22. Zannad F, McMurray JJV, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21
23. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
24. Vogt L, Waanders F, Boomsma F et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999-1007
25. Buter H, Hemmelder MH, Navis G et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13: 1682-1685 (Pubitemid 28306794)
26. Slagman MC, Waanders F, Hemmelder MH et al.; Holland Nephrology Study Group. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. Br Med J 2011; 343: d4366